With your support, we have been able to fund outstanding research, leading toward cures and improved quality of life for children with cancer. Browse through more than 1,000 funded projects below.
Use the search tool to refine your results. You can also click on a heading to sort by project title, institution name, or year the grant was awarded. Click on the project title to read more information.
You can learn about ALSF's grant review process here.
ALSF Funded Research Projects
|Project Title||Institution / Principal Investigator(s)||Grant Type||Year||State|
|Developing Novel Transcription Factor PROTACs to Disrupt the HMGA1 Epigenome in Relapsed Leukemia||The Johns Hopkins University School of Medicine / Linda Resar, MD and Jian Jin, PhD||Innovation Grants||2022||Maryland|
|Molecular circuitry of fibrolamellar carcinoma||Massachusetts General Hospital / Nabeel Bardeesy, PhD||Innovation Grants||2022||Massachusetts|
|Targeted nanoparticle-mediated “cold”-to-“hot” reprogramming of the tumor microenvironment of high-risk neuroblastoma||University of Massachusetts Chan Medical School / Prabhani Atukorale, PhD & Jason Shohet, MD, PhD||Innovation Grants||2022||Massachusetts|
|Isoform-specific TNC-redirected T cell Therapy for DIPG||St. Jude Children’s Research Hospital / Stephen Gottschalk, MD and Giedre Krenciute, PhD||Innovation Grants||2022||Tennessee|
|Developing Novel Transcription Factor PROTACs to Disrupt the HMGA1 Epigenome in Relapsed Leukemia||Icahn School of Medicine at Mount Sinai / Linda Resar, MD and Jian Jin, PhD||Innovation Grants||2022||New York|
|Developmental origins of leukemia in Down Syndrome||University of Rochester / James Palis, MD & Laurie Steiner, MD||Innovation Grants||2022||New York|
|Targeted nanoparticle-mediated “cold”-to-“hot” reprogramming of the tumor microenvironment of high-risk neuroblastoma||University of Massachusetts Amherst / Prabhani Atukorale, PhD & Jason Shohet, MD, PhD||Innovation Grants||2022||Massachusetts|
|Inhibition of translation initiation as a novel therapeutic strategy against MYCN-amplified neuroblastoma||Dana-Farber Cancer Institute / Rani George, MD, PhD||Innovation Grants||2022||Massachusetts|
|Epigenetic Enhancement of MHCI to Augment Neuroblastoma Immunotherapy||University of Wisconsin - Madison / Paul Sondel, MD, PhD and Amy Erbe-Gurel, PhD||Innovation Grants||2022||Wisconsin|
|Blocking the Evil Messenger in MYCN-driven High-risk Neuroblastoma||Boston University / Hui Feng, Md, PhD||Innovation Grants||2022||Massachusetts|